BridgeBio Pharma stands at a critical inflection point in its evolution from development-stage biotech to commercial pharmaceutical company. With the

Overview and Financial Model LifeArc is a UK-based medical research charity with a unique financial model, operating more like an

Habana Gaudi2 and Gaudi3 Accelerators Intel’s Gaudi2 (2022) and Gaudi3 (2024) AI accelerators target training of large models with

Advanced Micro Devices (AMD) has emerged as a significant challenger to NVIDIA's long-standing dominance, pursuing an aggressive strategy

The convergence of artificial intelligence (AI), accelerated computing hardware, and vast biological datasets is transforming healthcare and biotech into a

Global pharmaceutical and biotech deals surge with $15+ billion in transactions The pharmaceutical and biotechnology sectors witnessed significant deal activity

Valuing a biotech venture is a bit like valuing a promising but precarious alchemical experiment – full of potential magic, but

Avalyn Pharma represents a compelling yet high-risk opportunity in the rapidly evolving pulmonary fibrosis therapeutics market. The company's

Tang Capital's contrarian strategy targets the 300 "zombie" companies holding $30 billion in trapped capital In

Overview of Digital Therapeutics and Reimbursement Digital therapeutics (DTx) are evidence-based software interventions prescribed to treat or manage medical conditions.